UPDATE -- Alamar Biosciences and Nightingale Health to Lead UK Biobank 80,000-Sample Neurodegenerative Disease Study
Supported The Michael J Fox Foundation for Parkinson's Research, Alzheimer's Research UK and LifeArc, the study targets earlier detection, prevention and treatment of Parkinson’s disease, Alzheimer’s disease and other neurodegenerative conditions including rare dementias Supported The Michael J Fox Foundation for Parkinson's Research, Alzheimer's Research UK and LifeArc, the study targets earlier detection, prevention and treatment of Parkinson’s disease, Alzheimer’s disease and other neurodegenerative conditions including rare dementias
Covered in this story
Call it yourself
No calls on $ALMR yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Alamar Biosciences →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.